[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.150.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 321
Citations 0
Comment & Response
February 2015

The Value of Pharmacogenetic Testing

Author Affiliations
  • 1George Washington University, Washington, DC
JAMA Intern Med. 2015;175(2):314. doi:10.1001/jamainternmed.2014.7017

To the Editor In their August 2014 editorial, “Warfarin, Genes, and the (Health Care) Environment,” Kazi and Hlatky1 point out a number of plausible reasons why pharmacogenetic data in this setting did not make a significant difference in the clinical outcomes measured. They then argue that effects on “surrogate markers, such as drug levels” are insufficient to recommend widespread pharmacogenetic testing, yet such testing, like any diagnostic testing, should not be performed in a “widespread” way but only when clinically indicated.

First Page Preview View Large
First page PDF preview
First page PDF preview
×